Updated results from the IMvigor 210 trial demonstrate durable responses in metastatic urothelial cancer, even in patients with poor prognostic factors. Medscape Medical News

Related Links:

ConclusionEvolution and prognosis evaluation remain hard and could necessitate a radical surgery. Prognosis criteria for the bladder PEComas have to be clarified.

Publication date: Available online 9 August 2018Source: Actas Urológicas Españolas (English Edition)Author(s): J.A. March-Villalba, J. Panach-Navarrete, M.J. Herrero-Cervera, S. Aliño-Pellicer, J.M. Martínez-JabaloyasAbstractIntroductionTo study the relationship between quantitative mRNA determination (hTERT) in patients with bladder tumor, history of bladder tumor, and in subjects without a history of this neoplasia.Material and methodsA prospective randomized controlled study with 91 subjects included. The value of mRNA-hTERTN was determined in 63 patients with a history or suspicion of bladde…

Publication date: Available online 9 August 2018Source: Actas Urológicas Españolas (English Edition)Author(s): F. Gómez-Veiga, A. Alcaraz-Asensio, J. Burgos-Revilla, J. Cózar-OlmoAbstractObjectiveTo put forth new findings of urologic oncology with an impact on clinical practice presented during 2017 in the main annual meetings.MethodsThis document reviews abstracts on prostate, kidney and bladder cancer presented at the congresses of 2016 (EAU, AUA, ASCO, ESMO and ASTRO) and publications with the highest impact in this period valued with the highest scores by the OncoForum committee.ResultsAmong…

For many of us, a car is a sign of independence. But this emotional connection to our automobiles is part of what makes convincing a person that he or she is no longer capable of driving such a volatile battle. The longer adult children or others wait to discuss driving issues with a loved one, the harder it can be.
Read more on HealthCentral about how to help memory-impaired loved ones stop driving:
MedicareFAQ – Medicare Resource Center
Support a caregiver or jump-start discussion in support groups with real stories – for bulk orders of Minding Our Elders e-mail Carol  

    &nbsp…

Source: Minding Our EldersCategory: Geriatrics Authors: Source Type: blogs

AbstractExcision of port site (PSE) for patients having undergone laparoscopic cholecystectomy (LC) is not a standard recommendation. We retrospectively evaluated a cohort of patients with isolated PSM without any prior cancer-directed therapy who were assessed for resection between March 2012 and July 2016 at Tata Memorial Hospital, Mumbai. Eleven of a total 13 patients underwent wide excision for PSM in the given time period. Upfront resection was undertaken in six patients while seven patients received neoadjuvant chemotherapy (NACT) and two received neoadjuvant chemo radiotherapy (NACTRT) prior to attempted resection. …

Publication date: 9 August 2018Source: Cell, Volume 174, Issue 4Author(s): A. Gordon Robertson, Jaegil Kim, Hikmat Al-Ahmadie, Joaquim Bellmunt, Guangwu Guo, Andrew D. Cherniack, Toshinori Hinoue, Peter W. Laird, Katherine A. Hoadley, Rehan Akbani, Mauro A.A. Castro, Ewan A. Gibb, Rupa S. Kanchi, Dmitry A. Gordenin, Sachet A. Shukla, Francisco Sanchez-Vega, Donna E. Hansel, Bogdan A. Czerniak, Victor E. Reuter, Xiaoping Su

Source: CellCategory: Cytology Source Type: research

This study provides a dendritic cell-based vaccine strategy which might reduce the risk of tumor recurrence and improve the efficiency of anti-chemoresistance of bladder cancer.
PMID: 30084800 [PubMed – in process]

An existing body of literature shows that marital status and related social support are connected with disease outcomes.

Source: CancerNetworkCategory: Cancer & Oncology Authors: Source Type: news

Conclusion: Sarcopenia is present in a considerable proportion of patients with MIBC undergoing upfront cisplatin-based chemotherapy before planned RC. SMI decreases during treatment, but neither baseline SMI nor its kinetics is associated with response to chemotherapy.Urol Int 2018;101:1 –4

Condition:   Safety Issues Intervention:   Drug: Atezolizumab Sponsor:   McGill University Health Center Recruiting

Source: ClinicalTrials.govCategory: Research Source Type: clinical trials





Source link

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Enter Captcha Here : *

Reload Image